Core Viewpoint - WuXi AppTec (02268) has seen a significant stock price increase, with a rise of over 8% during trading, currently up 6.6% at HKD 62.2, with a trading volume of HKD 253 million. The company has issued a positive earnings forecast for 2025, leading to a slight adjustment in revenue and adjusted net profit predictions for 2025-2027 by 1-3% [1] Group 1: Financial Forecasts - The adjusted revenue forecasts for 2025-2027 are set at RMB 5.88 billion, 8.28 billion, and 11.11 billion respectively, while the adjusted net profit forecasts are RMB 1.60 billion, 2.45 billion, and 3.42 billion, corresponding to a compound annual growth rate (CAGR) of 38% and 46% for the respective years [1] - The strong growth is primarily attributed to the rapid increase in comprehensive CMC orders, particularly from late-stage clinical and commercialization phase contributions [1] Group 2: Market Trends - In the first two months of 2026, there were 25 financing events in the global XDC sector, a significant increase from 18 events in the same period of 2025 [1] - The number of BD transactions for XDC candidate drugs has remained stable, with a substantial increase in total upfront payments [1] - Since the beginning of 2024, there has been a gradual increase in the number of financing events, BD transactions, and total upfront payments in the XDC field, indicating sustained market activity [1] Group 3: Industry Position - The ongoing activity in financing and BD transactions is expected to further enhance downstream demand in the XDC CRDMO industry [1] - WuXi AppTec, as a leading company with strong technical capabilities and integrated delivery capabilities, is well-positioned to benefit from this important trend and expand its market share [1]
药明合联盘中涨超8% 公司有望持续受益XDC CRDMO行业下游需求改善趋势